此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Carrelizumab、化疗和阿帕替尼在可切除食管鳞状细胞癌新辅助治疗中的应用

Carrelizumab联合化疗和抗血管生成药物用于可切除食管鳞状细胞癌新辅助治疗的前瞻性、单臂、单中心临床研究

China with high incidence of esophageal cancer, the number of new cases and deaths account for about 50% of the world every year. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous cell carcinoma patients was not significantly decreased.

For patients with locally advanced esophageal cancer, direct surgery is not effective. It is difficult to achieve radical resection by surgery merely, and even if many patients receive surgery, they may eventually have tumor recurrence and poor survival rate. Therefore, it is necessary to explore effective perioperative neoadjuvant treatment to reduce the risk of postoperative recurrence and improve the postoperative survival rate of patients.

According to the reports, the expression of PD-L1 in esophageal cancer was about 41.4%. Therefore, PD-1/ PD-L1 immunocheckpoint inhibitor may become a new method for the treatment of esophageal cancer. Preliminary clinical results showed that immunotherapy combined with chemoradiotherapy provided a synergies antitumor effect. Multiple clinical results showed that Carrillizumab provided higher overall response rate for advanced esophageal cancer.

However, in patients with locally advanced esophageal cancer, the efficacy of Carrillizumab combined with chemotherapy and apatinib for sequential radical surgery is still unclear. The purpose of this study is to observe and evaluate the efficacy and safety of Carrillizumab combined with chemotherapy and antiangiogenic drugs in the neoadjuvant therapy of resectable esophageal squamous cell carcinoma.

研究概览

详细说明

Esophageal cancer is a common malignant tumor of the digestive tract. Every year, there are about 400,000 new cases of esophageal cancer in the world and about 300,000 people dying of this disease. China with high incidence of esophageal cancer, the number of new cases and deaths account for about 50% of the world every year. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous cell carcinoma patients was not significantly decreased. Early local invasion, lymph node metastasis and distant metastasis are the main causes of poor prognosis for the patients with esophageal squamous cell carcinoma.

For patients with locally advanced esophageal cancer, direct surgery is not effective. It is difficult to achieve radical resection by surgery merely, and even if many patients receive surgery, they may eventually have tumor recurrence and poor survival rate. Therefore, it is necessary to explore effective perioperative neoadjuvant treatment to reduce the risk of postoperative recurrence and improve the postoperative survival rate of patients.

In recent years, PD-1 antibody is undoubtedly the most dazzling star in the field of tumor therapy. It shows excellent efficacy in of the different kind of tumors. According to the reports, the expression of PD-L1 in esophageal cancer was about 41.4% (Meta-analysis of 1350 Chinese and Japanese subjects showed that the over-expression of PD-L1 tended to decrease overall survival). Therefore, PD-1/ PD-L1 immunocheckpoint inhibitor may become a new method for the treatment of esophageal cancer. Preliminary clinical results showed that immunotherapy combined with chemoradiotherapy provided a synergies antitumor effect. Multiple clinical results showed that Carrillizumab provided higher overall response rate for advanced esophageal cancer. It also provided superior progression free survival and overall survival compared with Pembrolizuma and paclitaxel. 2020 Chinese Society Of Clinical Oncology esophagus cancer guidelines recommended Carrillizumab as the first level for squamous cell carcinomas.

However, in patients with locally advanced esophageal cancer, the efficacy of Carrillizumab combined with chemotherapy and apatinib for sequential radical surgery is still unclear. The purpose of this study is to observe and evaluate the efficacy and safety of Carrillizumab combined with chemotherapy and antiangiogenic drugs in the neoadjuvant therapy of resectable esophageal squamous cell carcinoma.

研究类型

介入性

注册 (实际的)

42

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • China
      • Hangzhou、China、中国、310009
        • 2nd Affiliated Hospital, School of Medicine, Zhejiang University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. signed informed consent;
  2. patients age 18 to 75 years old
  3. primary resectable, histologically confirmed esophageal squamous cell cancer;
  4. Esophageal squamous cell carcinoma the clinical stage was IIA-IVA (according to AJCC TNM stage, 8th edition).
  5. ECOG PS 0-1.
  6. No distant metastasis, the diseases could be resectable assessed by thoracic oncologist;

Exclusion Criteria:

  1. with significant cardiovascular disease;
  2. current treatment with anti-viral therapy or HBV;
  3. Female patients who are pregnant or lactating;
  4. history of malignancy within 5 years prior to screening;
  5. active or history of autoimmune disease or immune deficiency;
  6. signs of distant metastases.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Carillizumab

Preoperative neoadjuvant therapy for 2-3 cycles. Radical surgery is performed 4-6 weeks after the last dose. Postoperative radiotherapy is determined according to the clinical situation and pathological stage of the patient.

Carillizumab can be maintained for a maximum of 1 year. During the study, patients were be followed until disease progression, withdrawal of informed consent, loss of follow-up, or death.

administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.

其他名称:
  • 食管切除术
  • 从参与者那里收集样本

Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma

Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Pathological Complete Response (PCR)
大体时间:1 month after surgery

No residual invasive tumor cells were found in the pathological examination of resected specimens.

1 month after surgery

次要结果测量

结果测量
措施说明
大体时间
Incidence of Treatment-related Adverse Events
大体时间:1 month after surgery

Incidence of Treatment-related Adverse Events as Assessed by CTCAE v5.0

1 month after surgery
Major Pathological Response (MPR)
大体时间:1 month after surgery

In the pathological examination of resected specimens, the proportion of residual tumor cells was less than 10%.

1 month after surgery
Objective Response Rate (ORR)
大体时间:1 month after surgery

The proportion of subjects with imaging PR or CR assessed according to RECIST 1.1 criteria

1 month after surgery
2-year and 5-year overall survival
大体时间:2-year and 5-year after surgery

The proportion of all study cases in which no death from any cause occurred within 2 years and 5 years after surgery

2-year and 5-year after surgery
2-year and 5-year disease-free survival
大体时间:2-year and 5-year after surgery

No recurrence, distant metastasis, or death within 2 years and 5 years after surgery accounted for the proportion of all cases studied.

2-year and 5-year after surgery
R0 resection rate
大体时间:1 month after surgery

The pathological results showed that the incision margin was negative and no residual cancer cells were found under the microscope

1 month after surgery
The changes in the peripheral blood immunoprofile among non-PCR (NPCR) and PCR patients
大体时间:3 month after surgery

By using mass spectrometry (CyTOF) and bioinformatics pipelines, we comprehensively characterized the immune landscape in the peripheral blood of ESCC patients before and after anti-PD-1 immunotherapy, aiming to explore the immune subsets correlated with neoadjuvant immunotherapy response

3 month after surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Weilin Wang、2nd Affiliated Hospital, School of Medicine, Zhejiang University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年11月23日

初级完成 (实际的)

2022年12月31日

研究完成 (估计的)

2030年11月1日

研究注册日期

首次提交

2020年12月3日

首先提交符合 QC 标准的

2020年12月10日

首次发布 (实际的)

2020年12月14日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅